Skip to content

Point of Care Peritoneal Dialysis System Early Evaluation Study

A Mixed Methods Early Evaluation Study To Assess The Safety, Efficacy and Usability Of A Point of Care Peritoneal Dialysis System When Used By Patients In The Home

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12622000078752
Acronym
POC-PDEE
Enrollment
1
Registered
2022-01-21
Start date
2022-06-29
Completion date
2023-01-31
Last updated
2022-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The Point of Care Peritoneal Dialysis System Early Evaluation Study (POC-PDEE) will utilise different methodologies to establish the safety, efficacy and usability of the Ellen Medical - Point of Care (EM-POC) peritoneal dialysis system with Australian dialysis patients as a key step in the system evaluation. This study comprises three inter-linked components: (1) a series of human factors usability assessments, (2) a shadow study testing the reliability of the chemical composition and sterility of PD fluid produced by the EM-POC system when used by dialysis patients or their carers independently at the point-of-care and (3) patient perspectives regarding the EM-POC system, it’s usability and the training provided prior to using the EM-POC system will be sought through semi-structured interviews.

Interventions

POC-PDEE will utilise different methodologies to establish the safety, efficacy and usability of the Ellen Medical - Point of Care (EM-POC) peritoneal dialysis (PD) system with Australian dialysis patients. This study comprises three inter-linked components: (1) a series of human factors usability assessments, (2) a shadow study testing the reliability of the chemical composition and sterility of PD fluid produced by the EM-POC system when used by dialysis patients or their carers independently

POC-PDEE will utilise different methodologies to establish the safety, efficacy and usability of the Ellen Medical - Point of Care (EM-POC) peritoneal dialysis (PD) system with Australian dialysis patients. This study comprises three inter-linked components: (1) a series of human factors usability assessments, (2) a shadow study testing the reliability of the chemical composition and sterility of PD fluid produced by the EM-POC system when used by dialysis patients or their carers independently at the point-of-care and (3) semi-structured interviews to assess patient perspectives regarding the EM-POC system, it’s usability and the training provided prior to using the EM-POC system. (1) Human Factors Assessment. A mixed methods study to collect observational and interview data from patient and clinician participants, who will be asked to complete specified tasks through simulated use testing, using: photographs, computer aided design (CAD) models, foam models and functional prototypes of the EM-POC system to identify potential human factors risk, use errors and possible improvements to the design of the system. The system prototypes used in these evaluations will not provide medical therapy. Assessments will be conducted individually with around 23 participants (approximately 20 patients and 3 clinicians) and will be conducted in patient participants’ homes or in the peritoneal dialysis unit. Assessments will be conducted by a human factors expert with over 20 years of experience in medical device product development and will last approximately 90 minutes. (2) Shadow Study. An open label in-vitro interventional study to test the chemical composition and sterility of PD fluid produced by patient participants using the EM-POC system at home. EM-POC PD fluid will NOT be used for dialysis in any participants. Instead, five patient participants will prepare four bags of PD fluid each day for five days at home using the EM-POC system. The filled PD bags will be collected and sent for testing of chemical composition and sterility. Participants will be trained to use the EM-POC system by a peritoneal dialysis clinical nurse specialist. Adherence will be monitored by daily visits to participants’ homes and collection of filled dialysis bags. (3) Patient Perspectives. A qualitative research study collecting data through semi-structured interviews from all five participants in the Shadow Study regarding their expectations, experiences and training with the EM-POC system. Daily participant experience will also be collected using a brief questionnaire. All interviews will be conducted via videoconference by an interviewer with extensive experience in qualitative research methods and patient partnership. Interviews will be recorded using videoconference software and transcribed to facilitate data analysis. Interviews will be conducted once with each participant, between one-three weeks following completion of the Shadow Study and take less than 60 minutes.

Sponsors

Ellen Medical Devices Pty Ltd
Lead SponsorCommercial sector/Industry

Study design

Allocation
Non-randomised trial
Intervention model
Other
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Patient Participants: 1. Aged between 18 years and 80 years (inclusive); 2. Willing and able to participate in the study; 3. Treated with peritoneal dialysis for a minimum of 6 months (either automated peritoneal dialysis or continuous ambulatory peritoneal dialysis); 4. Able to speak sufficient English to be trained safely in the EM-POC dialysis system and understand the training materials; 5. Provide written informed consent; 6. At-home requirements: The participant’s home must have an electricity supply and a supply of potable water. 7. Received a full course of vaccinations against COVID-19 as per contemporary NSW Health advice Clinician Participants: 1. Physicians or nursing staff with at least 12 months experience of PD

Exclusion criteria

Patient participants: 1. Expecting a planned procedure, dialysis modality change or transplant during the study; 2. Any condition or anticipated complication which in the opinion of the investigator would prevent compliance with study protocols or completion of the study

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026